Kiromic BioPharma (OTC:KRBP) Stock, Quote.Headers.trade-ideas

Kiromic BioPharma

Kiromic BioPharma Inc is a biotechnology company. It is an artificial intelligence (AI) driven, end-to-end allogeneic cell therapy company, currently developing the multi-indication allogeneic T cell therapy that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors. The company is a gene-editing which utilizes artificial intelligence and a proprietary neural network platform with a therapeutic focus on immuno-oncology.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

AAOI

ACCD

ALVO

APPS

APYX

ATXG

AUPH

BACK

BTTR

BXRX

CBAY

CNVS

CTMX

EIGR

EOSE

EVLO

FHTX

FLWS

GSUN

HILS

iMedia Brands, Inc. - 8.5% Senior Notes Due 2026

IMBIL

KRBP

Kintara Therapeutics, Inc. - Common Stock

KTRA

MVIS

Nuveen California Dividend Advantage Municipal Fund 2

OTRK

PALT

PIII

RNLX

ROOT

SRGA

UNCY

XPEV

Gainers


	Addentax Group Corp. (NASDAQ: ATXG) shares jumped 47.3% to $9.68. Addentax Group is launching automation of artificial intelligence internet operational tools project with top Games-as-a-Service firms.


Why Cineverse Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Pre-Market Outlook

AWIN

GNFT

LGHL

MICS

SCOR

SISI

TRUP

WAVE

Gainers


	Renalytix Plc (NASDAQ: RNLX) shares surged 48.7% to $3.02 in pre-market trading after the company received FDA De Novo marketing authorization for its KidneyIntelX.dkd prognostic test.


Why Renalytix Are Trading Higher By Over 48%; Here Are 20 Stocks Moving Premarket

Biotech

Health Care

General

Kiromic BioPharma Inc (NASDAQ: KRBP) shares are gaining Wednesday morning. However, there is no specific news today. During the session, the share price reached $9.22.

What&#39;s Going On With Kiromic BioPharma Stock Wednesday

KIROMIC BIOPHARMA INC by Kiromic BioPharma, Inc.

Kiromic BioPharma Inc

GPUS

Hyperscale Data CEO Says Received Inquiries From Wide Range Of Companies Interested In Exploring Our Michigan Facility; Engaged In Discussions With Potential IO Companies Interested In Leasing Michigan Data Center; Plan To Distribute Remaining Non-Core Assets To Stockholders Via One Or More Special Distributions

WIIM

RVNC

Revance Therapeutics shares are trading lower after the company announced it extended its merger agreement deadline with Crown Laboratories amid ongoing discussions.

Cantor Fitzgerald analyst Andres Sheppard reiterates EVgo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGO#NASDAQ">EVGO</a>) with a Overweight and maintains $5 price target.

Price Target

Reiteration

Analyst Ratings

EVGO

Cantor Fitzgerald Reiterates Overweight on EVgo, Maintains $5 Price Target

Innovative Eyewear Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) shares are trading lower by 19.0% to $8.73 during Monday&#8217;s session after the company announced the exercise of <a href="https://www.benzinga.com/pressreleases/24/09/n40978125/innovative-eyewear-inc-announces-exercise-of-warrants-for-2-6-million-gross-proceeds">$2.6 million worth of warrants</a>.
What Else: Innovative Eyewear has entered agreements for the exercise of outstanding warrants to purchase 263,160 shares of common stock. The warrants, initially priced at $9.50 per share, will now be exercised at $9.875 per share. 
The transaction, expected to close on September 24, should bring in approximately $2.6 million in gross proceeds, which will be used for working capital and corporate purposes.
H.C. Wainwright &amp; Co. is serving as the placement agent for the deal. In return for the immediate cash exercise, the company will issue new unregistered Series E and F warrants for additional shares, with exercise prices of $9.50 per share, and expiration periods of five years (Series E) and eighteen months (Series F).
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40983043/us-services-growth-tops-estimate-contraction-in-manufacturing-worsens-reacceleratio">U.S. Services Growth Tops Estimate, Contraction In Manufacturing Worsens</a>
<h2 class="wp-block-heading">Is LUCY A Good Stock To Buy?</h2>
An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages &#8211; like <a href="https://www.benzinga.com/quote/LUCY">Innovative Eyewear</a>&#8216;s page for example &#8211; there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.
These are known as capital allocation programs. Innovative Eyewear does not pay a dividend, but obviously has a few ways it can return value to shareholders. Feel free to search Benzinga's <a href="https://www.benzinga.com/calendars/dividends">dividend calendar</a> for the next company that is due to pay a dividend and determine what kind of yield you can earn for holding a share of the company.
For example, if you're looking to earn an annualized return of 12.78%, you'll need to buy a share of Two Harbors Inv by the Oct. 1, 2024. Once done, you can expect to receive a nominal payout of $0.45 on Oct. 29, 2024.
Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on <a href="https://www.benzinga.com/quote/LUCY">Innovative Eyewear</a> will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, LUCY has a 52-week high of $27.20 and a 52-week low of $3.26.

LUCY

Why Innovative Eyewear (LUCY) Stock Is Down 20% Today

Hyperscale Data Emphasizes the Potential of Its Data Center Business
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fhyperscaledata.com%2F&amp;esheet=54125848&amp;newsitemid=20240923800000&amp;lan=en-US&amp;anchor=Hyperscale+Data%2C+Inc.&amp;index=1&amp;md5=0699b0ad44b99c0eb7e267f5aa503cbe">Hyperscale Data, Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPUS#NYSE">GPUS</a>), a diversified holding company ("Hyperscale Data," or the "Company"), today shared a letter from its Chief Executive Officer to its stockholders.
Dear Stockholders,
I hope this message finds you well. I am pleased to share developments that underscore the potential of our Michigan data center amidst the ongoing artificial intelligence ("AI") evolution. We believe that our Michigan data center is an exceptional property, with 14 acres under roof and an additional 20 open acres for potential future development. This facility is powered by both nuclear and natural gas, providing clean power with a reduced environmental impact. With multiple fiber providers servicing the building and an infrastructure poised for expansion, we believe that our Michigan data center is strategically positioned to become our most valuable asset.

Hyperscale Data CEO Highlights Potential Of Michigan Data Center Amid AI Boom, Plans Expansion To 300 MW And Focus On AI Infrastructure

Elevai Labs Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELAB#NASDAQ">ELAB</a>) shares are trading lower by 60% to 11 cents during Monday&#8217;s session after the company announced the pricing of an <a href="https://www.benzinga.com/pressreleases/24/09/g40980018/elevai-labs-inc-announces-pricing-of-8-0-million-public-offering">$8.0 million public offering</a>.
What Else: The offering consists of 28.57 million shares of common stock or pre-funded warrants, each sold with one Series A Warrant and one Series B Warrant, both exercisable at $0.38 per share. 
The Series A Warrants will expire five years after the Initial Exercise Date, while Series B Warrants will expire in 2.5 years. Proceeds will support corporate purposes like working capital. 
The offering is expected to close around September 24, 2024, pending standard conditions.
Read Also: <a href="https://www.benzinga.com/markets/asia/24/09/40981254/chinese-vehicle-tech-faces-biden-administration-ban-over-national-security-concerns-china-ev-stocks">Chinese Vehicle Tech Faces Biden Administration Ban Over National Security Concerns</a>
<h2 class="wp-block-heading">Should I Sell My ELAB Stock?</h2>
Whether to sell or hold a stock largely depends on an investor's strategy and risk tolerance. Swing traders may sell an outperforming stock to lock in a capital gain, while long-term investors might ride out the turbulence in anticipation of further share price growth.
Similarly, traders willing to minimize losses may sell a stock that falls a certain percentage, while long-term investors may see this as an opportunity to buy more shares at a discounted price.
For analysis tools, charting data and access to exclusive stock news, check out <a href="https://pro.benzinga.com/">Benzinga PRO. Try it for free.</a>
ELAB has a 52-week high of $4.24 and a 52-week low of $0.11.

ELAB

Why Elevai Labs (ELAB) Stock Is Down 60% Today

Reported Earlier: Revance Therapeutics Denies Alleged Material Breaches Under Distribution Agreement With Teoxane, Extends Merger Agreement Deadline With Crown Laboratories To October 4, 2024 Amid Ongoing Discussions

Bank of America Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) said it is on track to launch over 165 new centers in 63 markets by the end of 2026,<a href="https://www.benzinga.com/pressreleases/24/09/n40977123/bofa-to-open-more-than-165-financial-centers-by-end-of-2026" target="_blank" rel="noreferrer noopener"> including nearly 40 centers this year</a>.
This expansion follows the opening of more than 100 centers in the last two years.
Bank of America is expanding its retail banking presence in Kentucky with the opening of its first financial center in the Louisville area today, followed by a second center set to open on October 7.
The bank plans to establish a total of five financial centers in the Louisville market by the end of 2025.
This latest expansion will increase Bank of America&#8217;s total number of financial centers in Kentucky to 10 by the end of 2027.
Since 2014, Bank of America has invested over $5 billion in growing its financial center network by opening locations in new and existing markets nationwide.
This month, Bank of America appointed Jim Rourke and Michael Liu to lead a new initiative integrating <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/09/40902762/bank-of-america-appoints-executives-to-lead-new-venture-report" rel="noreferrer noopener">investment banking and wealth management</a>.
The Private Client Partnership Development aims to boost asset growth and deal opportunities, focusing on sell-side M&amp;A.
Investors can gain access to the stock via&nbsp;First Trust Nasdaq Bank ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTXO#NASDAQ">FTXO</a>)&nbsp;and&nbsp;Invesco KBW Bank ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KBWB#NASDAQ">KBWB</a>).
Price Action: BAC shares are down 0.53% at $40.06 at the last check Monday.
Image via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40917216/elon-musk-says-warren-buffett-is-positioning-for-kamala-harris-win-with-his-277b-cash-pile-as-pr" target="_blank" rel="noreferrer noopener">Elon Musk Says Warren Buffett Is Positioning For Kamala Harris Win With His $277B Cash Pile As Pro-Trumper John Paulson Warns Of Equity Market Exit</a></li>
</ul>

Equities

Large Cap

FTXO

KBWB

Bank Of America Ramps Up Expansion: Over 165 New Financial Centers Set To Open Across 63 US Markets By 2026

Cantor Fitzgerald analyst Andres Sheppard reiterates Eve Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVEX#NYSE">EVEX</a>) with a Overweight and maintains $5 price target.

EVEX

Cantor Fitzgerald Reiterates Overweight on Eve Holding, Maintains $5 Price Target

Legal

California Attorney General Says California Files Lawsuit Against Exxon Mobil Over Role In Global Plastic Waste Pollution

Macro Notification

iShares MSCI Israel Capped Investable Market Index Fund

Israeli Military Says It Has Struck Approximately 800 Hezbollah Targets In Southern Lebanon And Bekaa Since This Morning

Minnesota Power Announces Plans For Two Large Solar Projects In Northern Minnesota, Aiming For Over 200 MW Capacity As Part Of Its EnergyForward Strategy For Carbon-Free Energy

Management

Global

ADTN

Automotive Seating Company Adient To Close Down Two Czech Production Plants, Cut 1,100 Jobs As Part Of Restructuring

Cantor Fitzgerald analyst Andres Sheppard reiterates Archer Aviation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) with a Overweight and maintains $10 price target.

ACHR

Cantor Fitzgerald Reiterates Overweight on Archer Aviation, Maintains $10 Price Target

<a href="https://www.chicagofed.org/publications/speeches/2024/sept-23-national-association-state-treasurers" title="https://www.chicagofed.org/publications/speeches/2024/sept-23-national-association-state-treasurers">https://www.chicagofed.org/publications/speeches/2024/sept-23-national-association-state-treasurers</a>

Federal Reserve

Goolsbee: Until This Recent Rate Cut, Falling Inflation Has Meant Fed Has Been Tightening Policy; The Cut Of 50 Bps To Start Makes Sense; We Are Shifting Back To A Normal Dual Mandate Mode; We Are 100s Of Basis Points Above The Neutral Rate; If Conditions Continue Like This There Are A Lot Of Cuts To Come Over Next 12 Months; We Have A Long Way To Come Down To Get The Interest Rate To Something Like Neutral

Hyperscale Data Shares Halted, News Pending

Wrapped eETH's (CRYPTO:WEETH) price has increased 3.47% over the past 24 hours to $2,784.52. Over the past week, WEETH has experienced an uptick of over 16.0%, moving from $2,391.30 to its current price. As it stands right now, the coin's all-time high is $4,196.87. 
The chart below compares the price movement and volatility for Wrapped eETH over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1727103821_0.png" alt="price_chart" />
The trading volume for the coin has decreased 67.0% over the past week, while the overall circulating supply of the coin has decreased 0.01% to over 1.58 million. The current market cap ranking for WEETH is #26 at $4.40 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1727103821_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Cryptocurrency Wrapped eETH's Price Increased More Than 3% Within 24 hours

- 2024 Bank of America European Autos and Future Car Virtual Conference&nbsp;&nbsp;&nbsp;

Guidance

Dividends

STLA

Stellantis CFO Says Special Dividend For Co Unlikely

Telsey Advisory Group analyst Cristina Fernandez maintains Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) with a Outperform and maintains $100 price target.

Telsey Advisory Group Maintains Outperform on Nike, Maintains $100 Price Target

Internet Computer's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">ICP</a>) price has increased 3.7% over the past 24 hours to $8.48. Over the past week, ICP has experienced an uptick of over 7.0%, moving from $7.99 to its current price. As it stands right now, the coin's all-time high is $700.65. 
The chart below compares the price movement and volatility for Internet Computer over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1727103752_0.png" alt="price_chart" />
Internet Computer's trading volume has climbed 53.0% over the past week, moving in tandem, directionally, with the overall circulating supply of the coin, which has increased 0.18%. This brings the circulating supply to 471.23 million. According to our data, the current market cap ranking for ICP is #30 at $4.00 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1727103752_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$ICP

Cryptocurrency Internet Computer's Price Increased More Than 3% Within 24 hours

Kiromic Biopharma (KRBP) has released an update. Kiromic BioPharma, Inc. has secured a financial boost by issuing a Senior Secured Convertible Prom...

Kiromic Biopharma Strikes $2M Convertible Debt Deal for Growth

Kiromic BioPharma files to withdraw registration statement

Kiromic Biopharma (KRBP) has issued an announcement. Kiromic BioPharma, Inc. is gearing up to share its corporate vision and strategy through a ser...

Kiromic Biopharma Outlines Vision in Stakeholder Meetings

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Kiromic BioPharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/krbp-stock-quote/">KRBP</a>) just reported results for the first quarter of 2024.<ul><li>Kiromic BioPharma reported earnings per share of -$1.00.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/krbp-stock-earnings-kiromic-biopharma-for-q1-of-2024/">KRBP Stock Earnings: Kiromic BioPharma Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

KRBP Stock Earnings: Kiromic BioPharma Reported Results for Q1 2024

The latest update is out from Kiromic Biopharma (KRBP). Kiromic BioPharma, Inc. has reached an agreement to transform $7.2 million of its high-inte...

Kiromic BioPharma's Strategic Financial Restructuring and Equity Shift

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Kiromic BioPharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/krbp-stock-quote/">KRBP</a>) just reported results for the second quarter of 2024.<ul><li>Kiromic BioPharma reported earnings per share of -74 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/krbp-stock-earnings-kiromic-biopharma-for-q2-of-2024/">KRBP Stock Earnings: Kiromic BioPharma Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

KRBP Stock Earnings: Kiromic BioPharma Reported Results for Q2 2024

Kiromic stock soars 65% on FDA fast track status for Deltacel

Press Releases

Kiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial Site

Kiromic BioPharma Reports Favorable Results at Six Weeks from Fourth Patient in Deltacel-01 Clinical Trial

Kiromic BioPharma Reports Six-Month Results from First Patient Enrolled in Deltacel-01 Clinical Trial

Kiromic BioPharma Provides Updates on its Deltacel-01 Clinical Trial

Kiromic BioPharma to Advance Deltacel-01 Clinical Trial to Part 2, Expansion Phase

Kiromic BioPharma Reports 20% Tumor Size Reduction at Eight Months in First Patient Enrolled in Deltacel-01

Kiromic BioPharma Provides Update on Part 1 of the Deltacel-01 Trial

Kiromic BioPharma's Deltacel Receives FDA Fast Track Designation

Kiromic BioPharma Advances Deltacel-01 Into Expansion Phase Following Safety Monitoring Committee's Unanimous Recommendation

Kiromic BioPharma Activates the University of Arizona Cancer Center as the Fifth Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Kiromic BioPharma

Kiromic BioPharma (KRBP) Forecast

Kiromic BioPharma (OTC:KRBP) Stock, Quote.Headers.trade-ideas